Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Marketed
NUPLAZID® (pimavanserin)[1]	Parkinson's Disease Psychosis					
DAYBUE™ (trofinetide)[2]	Rett Syndrome					
Pimavanserin[3]	Negative Symptoms of Schizophrenia					
ACP-101[4 5]	Hyperphagia in Prader-Willi Syndrome					
ACP-204[5]	Alzheimer's Disease Psychosis					
ASO Programs[6]	SYNGAP1; Rett; Undisclosed					
Undisclosed	Neuropsychiatric Symptoms					

[1] NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
[2] Acadia has an exclusive license to develop and commercialize trofinetide worldwide from Neuren Pharmaceuticals. DAYBUE (trofinetide) is only approved in the U.S. by the FDA for the treatment of Rett syndrome in adults and pediatric patients two years of age and older.
[3] Safety and efficacy of pimavanserin for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA.
[4] Acadia acquired Levo Therapeutics and its rights/licenses to ACP-101.
[5] ACP-101 and ACP-204 are investigational agents, and the safety and efficacy of these agents have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency.
[6] Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases; ASO = Antisense oligonucleotide.
Provided November 2, 2023 as part of an oral presentation and is qualified by such; contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.